Company Description
Viridian Therapeutics, Inc., a biotechnology company, discover and develops treatments for serious and rare diseases.
The company’s product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.
It also provides VRDN-006 a preclinical program for autoimmune disease. In addition, the company offers VRDN-006 and VRDN-008 a preclinical program for autoimmune disease.
The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021.Viridian Therapeutics, Inc. was founded in 2010 and is headquartered in Waltham, Massachusetts.
| Country | United States |
| Founded | 2006 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 94 |
| CEO | Stephen Mahoney |
Contact Details
Address: 221 Crescent Street, Suite 401 Waltham, Massachusetts 02453 United States | |
| Phone | 617 272 4600 |
| Website | viridiantherapeutics.com |
Stock Details
| Ticker Symbol | VRDN |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001590750 |
| CUSIP Number | 92790C104 |
| ISIN Number | US92790C1045 |
| Employer ID | 47-1187261 |
| SIC Code | 8071 |
Key Executives
| Name | Position |
|---|---|
| Stephen F. Mahoney J.D., MBA | Chief Executive Officer, President and Director |
| Seth Harmon | Senior Vice President of Finance and Accounting, Principal Financial and Accounting Officer |
| Thomas W. Beetham J.D., MBA | Chief Operating Officer |
| Dr. Eric N. Olson Ph.D. | Co-Founder and Chairman of Scientific Advisory Board |
| Dr. Michael R. Bristow M.D., Ph.D. | Co-Founder and Member of the Scientific Advisory Board |
| Dr. Marvin H. Caruthers Ph.D. | Co-Founder and Scientific Advisory Board Member |
| Vahe Bedian Ph.D. | Co-Founder and Scientific Advisor |
| Jennifer Tousignant J.D. | Chief Legal Officer |
| John A. Jordan | Vice President of Investor Relations and Corporate Communications |
| Melissa Manno | Chief Human Resources Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 12, 2024 | 10-Q | Quarterly Report |
| Nov 12, 2024 | 8-K | Current Report |
| Oct 18, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Sep 17, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Sep 13, 2024 | 424B5 | Filing |
| Sep 12, 2024 | 8-K | Current Report |